Market Overview
The global medical cyclotron market size was valued at USD 265.4 Million in 2025 and is projected to reach USD 493.8 Million by 2034, growing at a CAGR of 6.93% during 2026-2034. The market growth is driven by increasing cancer prevalence, advances in radiopharmaceuticals, rising demand for PET scans, and expanding healthcare infrastructure. Asia Pacific led the market in 2025 owing to robust healthcare investments and government initiatives. Key drivers include technological innovations and growing research activities.
Study Assumption Years
Base Year: 2025
Historical Year/Period: 2020-2025
Forecast Year/Period: 2026-2034
Medical Cyclotron Market Key Takeaways
The global medical cyclotron market size was valued at USD 265.4 Million in 2025.
The market is expected to grow at a CAGR of 6.93% during 2026-2034.
Forecasted market value is USD 493.8 Million by 2034.
Asia Pacific dominated the market in 2025 due to expanding healthcare infrastructure and increasing cancer prevalence.
Rising demand for diagnostic imaging procedures like PET scans is a vital growth driver.
Supportive government initiatives and technological innovations promote market growth.
Growing research activities and decentralized isotope production reinforce demand.
Sample Request Link: https://www.imarcgroup.com/medical-cyclotron-market/requestsample
Market Growth Factors
The increasing global incidence of cancer and cardiovascular diseases is a significant growth driver. In 2022, there were 9.7 million cancer deaths and 53.5 million people living with cancer diagnoses. Medical cyclotrons are crucial for producing radioisotopes for PET scans, enabling early cancer detection. Additionally, the rising prevalence of chronic diseases such as cardiovascular disorders and neurological conditions increases demand for precise diagnostic imaging methods.
Advancements in radiopharmaceuticals reinforce market growth. In 2024, the global radiopharmaceuticals market was valued at USD 5.8 Billion, projected to reach USD 8.9 Billion by 2033 with a CAGR of 4.9% (2025-2033). Innovations include more precise, targeted radiopharmaceuticals expanding applications beyond oncology to cardiology and neurology. AI and machine learning integration in radiopharmaceutical research have spurred development of new compounds, requiring novel radioisotopes produced by cyclotrons.
Expanding healthcare infrastructure and investments in advanced diagnostic imaging technologies also propel the market. For example, India had 1,69,615 Sub-Centres, 31,882 Primary Health Centres, 6,359 Community Health Centres, 1,340 Sub-Divisional/District Hospitals, 714 District Hospitals, and 362 Medical Colleges as of March 2023. Public and private sectors heavily invest in diagnostic imaging centers including PET and PET-CT. Furthermore, government policies enhancing access to advanced diagnostics and radiopharmaceutical availability foster medical cyclotron adoption.
Market Segmentation
Analysis by Type:
Ring Cyclotron: Largest component in 2025; favored for producing high-energy radioisotopes essential for PET scans. Known for continuous, efficient acceleration, high yields, purity, and consistency. Suitable for large-scale hospital production and supports diverse medical applications including cardiology and neurology.
Azimuthally Varying Field (AVF) Cyclotron: Included by report structure but no detailed data provided, hence excluded.
Analysis by Product Type:
Cyclotron 16-18 MeV: Leading product type in 2025. Offers optimal balance of production capacity and operational efficiency. Produces key isotopes like Fluorine-18 for PET imaging with high purity and sufficient yield, suitable for large hospitals and commercial radiopharmacies. Cost-effective with versatility for diverse diagnostic and therapeutic uses.
Analysis by End User:
Hospitals: Largest end user segment in 2025. Hospitals deploy cyclotrons for producing radioisotopes essential in PET and SPECT imaging to diagnose diseases like cancer, cardiovascular, and neurological disorders. In-house production reduces dependency on external suppliers, lowers costs, and improves efficiency in nuclear medicine.
Regional Insights
Asia Pacific held the largest market share in 2025, driven by expanding healthcare infrastructure in China, Japan, and India. Government investments, favorable policies, and rising cancer prevalence contribute significantly. The region benefits from increased adoption of PET imaging and robust R&D activities in nuclear medicine, maintaining its market dominance.
Recent Developments & News
February 2025: Nagpur State Government announced plans to establish a cyclotron center for cancer detection and nuclear research.
February 2025: Framatome partnered with IBA to advance alpha-emitting radioisotope Astatine-211 manufacturing in the US and Europe.
November 2024: NISER Bhubaneswar planned construction of a medical cyclotron facility for isotopes used in PET CT and SPECT-CT imaging.
October 2024: African Medical Centre of Excellence announced plans to establish a cyclotron for diagnosing and treating complex diseases including cancer and neurological disorders.
Key Players
Advanced Cyclotron Systems Inc.
Alcen
Best Medical International Inc.
General Electric Company
IBA RadioPharma Solutions
Ionetix Corporation
Isosolution Inc.
Siemens AG
Sumitomo Heavy Industries Ltd.
Varian Medical Systems Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
👉Get Custom Market Research for Your Business👈
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Write a comment ...